Huhn M, et al. - Given that antipsychotic drugs are the treatment of choice for schizophrenia, researchers performed a network meta-analysis of placebo-controlled and head-to-head randomized controlled trials to compare and rank 32 antipsychotics. From 54,417 identified citations, 402 studies with data for 53,463 patients were included. Compared to placebo, all antipsychotics led to a higher reduction in overall symptoms (although not statistically significant for six drugs). For reduction of positive symptoms, variation in standardized mean differences compared with placebo (31,179 participants), from −0.69 (95% CrI −0.86 to −0.52) for amisulpride to −0.17 (−0.31 to −0.04) for brexpiprazole was noted, for negative symptoms (32,015 participants) from −0.62 (−0.84 to −0.39; clozapine) to −0.10 (−0.45 to 0.25; flupentixol) was noted, for depressive symptoms (19,683 participants) from −0.90 (−1.36 to −0.44; sulpiride) to 0.04 (−0.39 to 0.47; flupentixol) was observed. These findings suggest that antipsychotics display some efficacy differences, but most of these differences are gradual. More marked differences in side-effects were evident. Considering these findings may aid clinicians in balancing risks vs benefits of those drugs available in their countries.